Essential Hypertension is characterized by endothelial dysfunction due to reduced nitric
oxide (NO) bioavailability. Impairment in nitric oxide-mediated vasodilatation in human
brachial, coronary, and renal arteries has been demonstrated in patients with essential
hypertension. Administration of L-arginine, a NO substrate yeld controversial results.
The purpose of the present study, double blind and matched for age, sex and body mass index
(BMI), is to assess the efficacy of L-arginine treatment on blood pressure (BP) control and
arterial stiffness in patients with stage1 hypertension.